BioXcel Therapeutics Inc BTAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BTAI is a good fit for your portfolio.
News
-
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
-
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
-
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
-
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
-
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
-
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
-
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
-
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Trading Information
- Previous Close Price
- $2.71
- Day Range
- $2.55–2.72
- 52-Week Range
- $1.91–29.56
- Bid/Ask
- $2.57 / $2.58
- Market Cap
- $78.58 Mil
- Volume/Avg
- 608,574 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 57.20
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 74
Comparables
Valuation
|
Metric
|
BTAI
|
MRNS
|
ICVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 4.69 | 3.30 |
Price/Sales | 57.20 | 2.50 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
BTAI
MRNS
ICVX
Financial Strength
|
Metric
|
BTAI
|
MRNS
|
ICVX
|
|---|---|---|---|
Quick Ratio | 2.39 | 3.79 | 17.59 |
Current Ratio | 2.65 | 4.07 | 18.06 |
Interest Coverage | −12.87 | −7.94 | — |
Quick Ratio
BTAI
MRNS
ICVX
Profitability
|
Metric
|
BTAI
|
MRNS
|
ICVX
|
|---|---|---|---|
Return on Assets (Normalized) | −111.90% | −59.45% | −29.30% |
Return on Equity (Normalized) | −2,033.74% | −195.80% | −31.87% |
Return on Invested Capital (Normalized) | −141.34% | −84.00% | −34.69% |
Return on Assets
BTAI
MRNS
ICVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rlsdcssmc | Qrck | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zslkhxf | Hflhz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lggfppq | Tmfmjz | $99.5 Bil | |
MRNA
| Moderna Inc | Pgtttjft | Wwjqw | $38.8 Bil | |
ARGX
| argenx SE ADR | Vwrwzxhc | Twqzb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cznzkhq | Wqyx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bqpbvnbbm | Jltbgr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ncffvcdb | Kpmlvh | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fktdhblmp | Stbndsk | $12.5 Bil | |
INCY
| Incyte Corp | Nppgbmhp | Sgprmb | $11.6 Bil |